Post-COVID-19 opsoclonus myoclonus syndrome
Sri Lanka Journal of Neurology · 2023
DOI: 10.4038/sljon.v10i1.146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sri Lanka Journal of Neurology, 2023. Verfasst von Branavan Sivagnanam und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Opsoclonus-myoclonus syndrome (OMS) is a rare neurological disorder, which most commonly is a paraneoplastic manifestation. We report a case of OMS occurring as an immunological sequalae of COVID-19.Case presentation: A 69-year-old woman developed subacute onset opsoclonus, multifocal myoclonus and truncal ataxia following moderately-severe COVID-19. Extensive evaluation revealed no underlying malignancy. There was only a partial response to steroids and intravenous immunoglobulin, but she significantly improved with plasmapheresis.
Conclusion
SARS-COV-2 infection can induce an immune-mediated OMS, which responds to plasmapheresis.
Zitieren
APA
Sivagnanam, B., & Chang, T. (2023). Post-COVID-19 opsoclonus myoclonus syndrome. Sri Lanka Journal of Neurology. https://doi.org/10.4038/sljon.v10i1.146
Vancouver
Sivagnanam B, Chang T. Post-COVID-19 opsoclonus myoclonus syndrome. Sri Lanka Journal of Neurology. 2023. doi:10.4038/sljon.v10i1.146
BibTeX
@article{Sivagnanam2023,
author = {Sivagnanam, Branavan and Chang, Thashi},
title = {Post-COVID-19 opsoclonus myoclonus syndrome},
journal = {Sri Lanka Journal of Neurology},
year = {2023},
doi = {10.4038/sljon.v10i1.146}
}
EUVIMED